相关实验视频
Updated: Jan 10, 2026

05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
18.3K
艾滋病毒治疗:抗病毒药物的最新发展 - - 范围审查
Francisco Fanjul1,2,3, Meritxell Gavalda2,4, Antoni Campins1,2
1Infectious Diseases Unit, Hospital Universitario Son Espases, 07120 Palma de Mallorca, Spain.
Biomedicines
|November 27, 2025
概括
新的艾滋病毒治疗侧重于新型药物点和输送系统,包括长效选择和广泛中和抗体,以克服耐药性和改善慢性艾滋病毒管理的坚持.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 艾滋病毒/艾滋病研究研究
背景情况:
- 抗逆转录病毒疗法 (ART) 已经推进了艾滋病毒管理,但药物耐药性,毒性,粘附性和病毒储存等挑战仍然存在.
- 这些挑战需要在抗艾滋病毒药物开发和交付平台上进行持续的创新.
- 最近的进展旨在解决这些未满足的艾滋病毒治疗和预防需求.
研究的目的:
- 对抗艾滋病毒药物和输送平台的最新发展进行范围审查.
- 在临床开发中识别新的分子和新的作用机制.
- 综合当前艾滋病毒治疗方法的进展.
主要方法:
- 从2020年1月到2025年9月,对主要数据库 (PubMed,Embase,Web of Science,Scopus) 进行了全面的文献搜索.
- 从2023-2025年开始,对来自主要艾滋病毒会议 (CROI,IAS/AIDS,IDWeek,HIV格拉斯哥) 的摘要进行选.
- 遵守PRISMA-ScR框架 (系统性审查的首选报告项目和范围审查的元分析扩展).
主要成果:
- 关键的发展包括囊抑制剂 (例如,莱纳卡帕维尔) 用于多药耐药性HIV和预防,以及长效注射剂 (cabotegravir/rilpivirine).
- 成熟抑制剂 (扎博菲拉维尔) 和附着抑制剂 (福斯特姆萨维尔) 代表了新的作用机制.
- 广泛中和抗体 (bNAbs) 显示出无ART抑制的潜力,超长效应的输送系统正在进展.
结论:
- 艾滋病毒药物管道正在扩大,包括新的点,组合策略和较少的剂量方案.
- 成功实施需要考虑耐药性,确保公平获取,并将医疗保健提供适应新技术的战略.
- 未来的方向强调了长期艾滋病毒管理和预防的创新解决方案.
关键词:
艾滋病病毒 艾滋病病毒 艾滋病病毒抗逆转录病毒药物治疗广泛中和抗体的抗体.这是一种capsid抑制剂.植入物植入物植入物植入物长效疗法 长效疗法成熟抑制剂的成长抑制剂纳米颗粒是一种纳米粒子.预防 预防 预防范围审查 范围审查审查更多相关视频
相关概念视频
Retrovirus Life Cycles
49.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.2K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Drug Administration and Therapy Phases: Overview
1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Subviral Agents
485
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
485
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Therapeutic Drug Monitoring: Overview and Classification
279
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
279

